Whether mouse or human, SCCs from various body sites have been shown to express at least one of the B7 family checkpoint proteins, such as PDL1, CD80, and CD276, to dampen cytotoxic T-cell activity within the tumor microenvironment and/or delivered by adoptive T-cell transfer therapy (Xu et al. 2014a; Miao et al. 2019; Wang et al. 2021). The gene discussed is CD80; the disease is neoplasm.